Compare BXMT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXMT | LQDA |
|---|---|---|
| Founded | 1966 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | N/A | 2018 |
| Metric | BXMT | LQDA |
|---|---|---|
| Price | $19.23 | $40.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $20.33 | ★ $38.60 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 02-11-2026 | 11-03-2025 |
| Dividend Yield | ★ 9.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $393,335,000.00 | $69,216,000.00 |
| Revenue This Year | N/A | $1,005.03 |
| Revenue Next Year | $16.34 | $204.13 |
| P/E Ratio | $30.86 | ★ N/A |
| Revenue Growth | N/A | ★ 343.41 |
| 52 Week Low | $16.51 | $11.26 |
| 52 Week High | $21.24 | $42.46 |
| Indicator | BXMT | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 66.99 |
| Support Level | $19.16 | $36.28 |
| Resistance Level | $19.62 | $40.60 |
| Average True Range (ATR) | 0.41 | 3.34 |
| MACD | -0.01 | 0.51 |
| Stochastic Oscillator | 54.19 | 86.82 |
Blackstone Mortgage Trust Inc is a real estate finance company involved in the origination and purchase of senior loans collateralized by commercial properties in North America, Europe, and Australia. The vast majority of the company's asset portfolio is comprised of floating rate loans secured by priority mortgages. These mortgages are mainly derived from office, hotel, and manufactured housing properties. A percentage of the collateralized real estate properties are located in New York, California, and the United Kingdom. Blackstone Mortgage Trust is managed by a subsidiary of The Blackstone Group and benefits from the market data provided by its parent company. Nearly all of Blackstone Mortgage Trust's revenue is generated in the form of interest income.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.